Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8061)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 26, 2020 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhou JH, Wu B, Wang WX, Lei F, Cheng X, Qin JJ, Cai JJ, Zhang X, Zhou F, Liu YM, Li HM, Zhu LH, She Z, Zhang X, Yang J, Li HL. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases 2020; 8(22): 5576-5588 [PMID: 33344548 DOI: 10.12998/wjcc.v8.i22.5576] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i22/5576.htm |
| Number | Citing Articles |
| 1 |
Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini. Managing diabetes in diabetic patients with COVID: where do we start from?. Acta Diabetologica 2021; 58(11): 1441 doi: 10.1007/s00592-021-01739-1
|
| 2 |
Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.895458
|
| 3 |
Anna Gorący, Jakub Rosik, Bartosz Szostak, Łukasz Ustianowski, Klaudia Ustianowska, Jarosław Gorący. Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. Viruses 2022; 14(5): 1092 doi: 10.3390/v14051092
|
| 4 |
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis. Primary Care Diabetes 2022; 16(1): 162 doi: 10.1016/j.pcd.2021.12.008
|
| 5 |
Yarini Arrebola Sánchez, Fabiola Almeida García, Daniel Ojeda del Sol, Mario E. Valdés-Tresanco, Carlos David Ortiz, Belinda Sánchez Ramírez, Isel Pascual Alonso. Dipeptidyl peptidase IV: a multifunctional enzyme with implications in several pathologies including cancer. Physical Sciences Reviews 2024; 9(8): 2541 doi: 10.1515/psr-2022-0288
|
| 6 |
Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021; 15(3): 777 doi: 10.1016/j.dsx.2021.03.027
|
| 7 |
Yang Yang, Ling Zhao, Yeying Wang, Chengjiang Liu, Tingyu Ke. Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes. International Journal of Diabetes in Developing Countries 2024; 44(3): 426 doi: 10.1007/s13410-023-01228-x
|
| 8 |
Djordje S. Popovic, Nikolaos Papanas, Anca Pantea Stoian, Ali A. Rizvi, Andrej Janez, Manfredi Rizzo. Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. Diabetes Therapy 2021; 12(12): 3037 doi: 10.1007/s13300-021-01170-3
|
| 9 |
Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint. Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3951144
|
| 10 |
Tianli Zhang, Xiang Tong, Shijie Zhang, Dongguang Wang, Lian Wang, Qian Wang, Hong Fan. The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.731453
|
| 11 |
Dimitrios Patoulias, Michael Doumas. Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. Endocrinology and Metabolism 2021; 36(4): 904 doi: 10.3803/EnM.2021.1048
|
| 12 |
Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint. Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis. Endocrinology, Diabetes & Metabolism 2022; 5(3) doi: 10.1002/edm2.338
|
| 13 |
Rifat Emral, Cem Haymana, Ibrahim Demirci, Ilker Tasci, Mustafa Sahin, Erman Cakal, Naim Ata, Ugur Unluturk, Tevfik Demir, Derun Ertugrul, Ibrahim Sahin, Aysegül Atmaca, Osman Celik, Murat Caglayan, Kazim Yalcin Arga, Selcuk Dagdelen, Serpil Salman, Ilhan Satman, Alper Sonmez. Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study. Diabetes Therapy 2021; 12(11): 2857 doi: 10.1007/s13300-021-01133-8
|
| 14 |
Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, Ioana Cristina Bica, Claudiu Teodorescu, Horia Păunescu, Oana Andreia Coman, Doina-Andrada Mihai, Anca Pantea Stoian. Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19. Biomedicines 2022; 10(10): 2624 doi: 10.3390/biomedicines10102624
|
| 15 |
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control. World Journal of Virology 2022; 11(6): 399-410 doi: 10.5501/wjv.v11.i6.399
|
| 16 |
Daniel J. Drucker. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metabolism 2021; 33(3): 479 doi: 10.1016/j.cmet.2021.01.016
|
| 17 |
Verena Schöning, Felix Hammann. Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients. Pharmaceutics 2022; 14(9): 1828 doi: 10.3390/pharmaceutics14091828
|
| 18 |
E. A. Ortenberg, L. A. Suplotova. Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review). Meditsinskiy sovet = Medical Council 2022; (10): 40 doi: 10.21518/2079-701X-2022-16-10-40-45
|
| 19 |
Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. Therapeutic Advances in Endocrinology and Metabolism 2021; 12 doi: 10.1177/2042018821996482
|
| 20 |
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, Sherly Lawrensia, Ian Huang. Diabetes and COVID-19: The past, the present, and the future. Metabolism 2021; 121: 154814 doi: 10.1016/j.metabol.2021.154814
|
| 21 |
Lijin Lin, Ze Chen, Ting Ding, Hui Liu, Feng Zhou, Xuewei Huang, Xingyuan Zhang, Weifang Liu, Bing-Hong Zhang, Yufeng Yuan, Peng Zhang, Xiao-Jing Zhang, Zhi-Gang She, Jingjing Cai, Wenping Chen, Hongliang Li. Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 4469 doi: 10.2147/DMSO.S332819
|
| 22 |
Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.708494
|
| 23 |
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang. The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies. Therapeutic Innovation & Regulatory Science 2024; 58(4): 773 doi: 10.1007/s43441-024-00633-6
|
| 24 |
Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior. The enzymes in COVID-19: A review. Biochimie 2022; 197: 38 doi: 10.1016/j.biochi.2022.01.015
|
| 25 |
I. I. Dedov, N. G. Mokrysheva, M. V. Shestakova, T. V. Nikonova, A. Yu. Mayorov, G. R. Galstyan, M. Sh. Shamhalova, V. O. Barysheva, A. S. Ametov, M. B. Antsiferov, A. Yu. Babenko, T. P. Bardymova, F. V. Valeeva, A. A. Vachugova, E. N. Grineva, T. Yu. Demidova, T. P. Kiseleva, M. A. Kunicyna, T. N. Markova, A. M. Mkrtumyan, N. A. Petunina, L. A. Ruyatkina, V. V. Saluhov, L. A. Suplotova, E. L. Hadarceva, Yu. Sh. Halimov. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus 2022; 25(1): 27 doi: 10.14341/DM12873
|
| 26 |
Li-Min Zhao, Xie-Hui Chen, Mei Qiu. Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology 2022; 12 doi: 10.3389/fendo.2021.825100
|
| 27 |
Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou. Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. Archives of Medical Research 2022; 53(2): 186 doi: 10.1016/j.arcmed.2021.08.002
|